Clinical Pipeline

Learn more about our pipeline

Trials for Market Approval

Download PPT

Pre-Clinical (GLP)

OTB-658

Institute of Materia Medica, CAMS & PUMC

FNDR 20364

National Centre of Oceanic and Antarctic Research (NCAOR), Gao, India

TB47

Guangzhou Institute of Respiratory Medicine Company Limited, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

GSK839

GlaxoSmithKline

CLB073

Bill & Melinda Gates Medical Research Institute

MBX-4888A

Microbiotix, Inc.

Phase 1

TBD09 (MK7762)

Bill & Melinda Gates Medical Research Institute, Merck & Co., Inc., NIAID, NIH, DHHS

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

GSK-286

GlaxoSmithKline, TB Drug Accelerator, Bill & Melinda Gates Foundation

Phase 1 Safety, Tolerability and Pharmacokinetics of GSK2556286

TBAJ-587, Diarylquinoline

TB Alliance, ERA4TB (European Regimen Accelerator for Tuberculosis), University of Auckland, Merck & Co., Inc.

TBI-223

TB Alliance, Institute of Materia Medica

TBI-223 Phase 1 MAD

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

Bill & Melinda Gates Medical Research Institute, Merck & Co., Inc.

Macozinone (MCZ, PBTZ-169)

iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation

Phase 2

DECISION

PAN-TB XBQS Trial

Bill & Melinda Gates Medical Research Institute

Quabodepistat (OPC-167832)

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2b/c. 4-month Regimen of OPC-167832, Delamanid and Bedaquiline for DS Pulmonary TB

PAN-TB XBQS Trial

Sanfetrinem

GlaxoSmithKline, Bill & Melinda Gates Foundation

Phase 2: EBA, Safety and Tolerability of Sanfetrinem Cilexetil

Sutezolid

Sequella, Inc, TB Alliance

Sutezolid Dose-finding and Combination Evaluation (SUDOCU)

PAN-TB XBQS Trial

BTZ-043

University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF), European and Developing Countries Clinical Trials Partnership (EDCTP), Radboud University

DECISION

TBAJ-876

TB Alliance, University of Auckland

NC-009 Trial

Alpibectir (BVL-GSK098)

BioVersys AG, GlaxoSmithKline

Phase 2 EBA: bEto TB

Ganfeborole (GSK 3036656)

GlaxoSmithKline, European Union Horizon 2020, NIAID, NIH, DHHS

Delpazolid (LCB01-0371)

LegoChem Biosciences, Inc.

DECODE- Delpazolid Dose-Finding and Combination Development Trial